Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06067438 · ClinicalTrials.gov registry record · Phase 2
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
A Phase 2 study of Atrial Fibrillation and Esophageal Carcinoma, sponsored by OHSU Knight Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT06067438 is a Phase 2 study of Atrial Fibrillation and Esophageal Carcinoma that is actively recruiting participants, run by OHSU Knight Cancer Institute. The registered enrollment target is 90 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06067438, a Phase 2 study of Atrial Fibrillation and Esophageal Carcinoma, is actively recruiting participants, sponsored by OHSU Knight Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well amiodarone works in the prevention of atrial fibrillation (AF) after a minimally invasive esophagectomy (MIE) in patients with esophageal cancer. Atrial fibrillation (AF) is an irregular heart rhythm, usually associated with a rapid rate, that is caused by abnormal electrical activity within the atria. AF is the most common complication after MIE for esophageal cancer. There has never been a study of AF after MIE that has used unbiased assignment of patients to receive preventative amiodarone or not. Further, there is no standard recommendation or guideline for preventative medications, such as amiodarone, to decrease the risk of AF in patients having MIE performed for cancer. In fact, most medical centers in the United States and around the world do not give preventative amiodarone after esophagectomy. Giving amiodarone after MIE surgery may be able to reduce the risk of AF for patients with esophageal cancer.
Conditions Studied
Interventions
- OTHER Saline
- DRUG Amiodarone Hydrochloride
Study Locations (1)
Oregon
- OHSU Knight Cancer Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-06-21 |
| Est. Completion | 2026-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06067438
The ClinicalTrials.gov registry entry for NCT06067438 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (97% lower). The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.
NCT06067438 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT06067438 about?
NCT06067438 is a clinical study titled "Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer". This phase II trial studies how well amiodarone works in the prevention of atrial fibrillation (AF) after a minimally invasive esophagectomy (MIE) in patients with esophageal cancer. Atrial fibrillation (AF) is an irregular heart rhythm, usually associated with a rapid rate, that is caused by abnorm...
What is the current status of trial NCT06067438?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2024-06-21. Estimated completion is 2026-08-30.
What conditions does trial NCT06067438 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Esophageal Carcinoma.
What interventions are being tested in trial NCT06067438?
The interventions under investigation include: Saline (OTHER), Amiodarone Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT06067438?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06067438 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study
RECRUITING · Phase 2
-
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
RECRUITING · Phase 2
-
A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation
RECRUITING · Phase 2
-
ECG Validation Study
ACTIVE NOT RECRUITING · Phase 2
-
A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.